Skip to main content

Table 1 Baseline characteristics for patients in CCRT group vs. chemotherapy group

From: Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for stage IV esophageal squamous cell carcinoma: a retrospective controlled study

Characteristics

CCRT (n = 55)

Chemotherapy (n = 86)

P

Sex

0.689

 Male

43 (78.2%)

64(74.4%)

 

 Female

12 (21.8%)

22 (25.6%)

 

Age, years

0.862

 ≤ 60

32 (58.2%)

48 (55.8%)

 

 > 60

23 (41.8%)

38 (44.2%)

 

Tumor location

0.674

 cervical

3 (5.5%)

3 (3.5%)

 

 upper thoracic

16 (29.1%)

19 (22.1%)

 

 middle thoracic

23 (41.8%)

38 (44.2%)

 

 lower thoracic

13 (23.6%)

26 (30.2%)

 

KPS score

0.467

 ≥ 80

45 (81.8%)

64(74.4%)

 

 < 80

10 (18.2%)

22 (25.6%)

 

T-stage

0.816

 T1–2

8 (14.5%)

15 (17.4%)

 

 T3–4

47 (85.5%)

71 (82.6%)

 

N-stage

0.797

 N0

6 (10.9%)

11 (12.8%)

 

 N+

49 (89.1%)

75 (87.2%)

 

Dysphagia score

0.096

 0 (asymptomatic)

4 (7.3%)

5 (5.8%)

 

 1 (eat solid diet with some dysphagia)

5 (9.1%)

23 (26.7%)

 

 2 (eat semisolid diet)

28 (50.9%)

36 (41.9%)

 

 3 (drink liquid diet)

13 (23.6%)

19 (22.1%)

 

 4 (complete dysphagia)

5 (9.1%)

3 (3.5%)

 

Number of metastatic organs

0.351

 Solitary metastasis

41 (74.5%)

57 (66.3%)

 

 Multiple metastasis

14 (25.5%)

29 (33.7%)

 

Metastasis sites

 

 Nonregional lymph nodes

14 (25.5%)

24 (27.9%)

0.831

 lung

14 (25.5%)

16 (18.6%)

 

 liver

17 (30.9%)

34 (39.5%)

 

 bone

21 (38.2%)

36 (41.9%)

 

 others

5 (9.1%)

8 (9.3%)

 

Chemotherapy regimens

 PTX + DDP

24 (43.6%)

42 (48.8%)

0.605

 5-Fu + DDP

31 (56.4%)

44 (51.2%)

 

Chemotherapy cycles

0.585

 > 2

20 (36.4%)

27 (31.4%)

 

 ≤ 2

35 (63.6%)

59 (68.6%)

 
  1. Abbreviations: CCRT concurrent chemoradiotherapy, KPS Karnofsky Performance Status, CDDP cisplatin, 5-FU 5-fluorouracil, PTX paclitaxel